Marker Therapeutics, Inc. (MRKR) intrinsic value & 10-year financials
Marker Therapeutics, Inc. (MRKR) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 35.4% a year to $3.5M, with an average return on invested capital of -651.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.04
- Market cap
- $15.9M
- Revenue (FY2025)
- $3.5M
- Revenue growth (10-yr CAGR)
- 35.4%
- ROIC (10-yr avg)
- -651.8%
- Free cash flow (FY2025)
- —
MRKR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $3.5M | -$12.2M | -$0.79 | — | -363.5% | -72.8% |
| FY2024 | $6.6M | -$10.7M | -$1.19 | — | -168.7% | -68.2% |
| FY2023 | $3.3M | -$8.2M | -$0.94 | — | -440.4% | -98.1% |
| FY2022 | $9.0M | -$29.9M | -$3.58 | — | -332.2% | -215.8% |
| FY2021 | $1.2M | -$41.9M | -$0.55 | — | -3179.3% | -272.4% |
| FY2020 | $466.8K | -$28.7M | -$0.61 | — | -6188.2% | -313.3% |
| FY2019 | $213.2K | -$21.4M | — | -$18.7M | -10567.3% | -4632.9% |
| FY2018 | $206.0K | -$148.0M | — | -$14.6M | -71930.1% | -470.4% |
| FY2017 | $183.1K | -$11.0M | -$1.16 | -$8.4M | -6371.1% | -237.0% |
| FY2016 | $231.2K | -$2.5M | -$0.72 | — | -3673.1% | -137.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Marker Therapeutics, Inc. is a consistent compounder, expanding top-line revenue at 35.4% annually over the past decade.
Marker Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -43.8% ROIC.
Marker Therapeutics, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Marker Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-26.24 per share.